Home / Business and Economy / Supernus and Indivior Unite in Stock Deal
Supernus and Indivior Unite in Stock Deal
3 Aug
Summary
- Companies merge via an all-stock agreement.
- New entity will generate approximately $2.2 billion annually.
- Focus on neurological, psychiatric, and addiction treatments.
Supernus Pharmaceuticals and Indivior Pharmaceuticals have agreed to an all-stock merger, a significant development announced on Monday. This union will establish a new pharmaceutical powerhouse with projected annual revenues of approximately $2.2 billion. The combined entity will boast a comprehensive portfolio of medicines designed to treat neurological, psychiatric, and addiction-related conditions.
The strategic combination aims to leverage the strengths of both companies to address a range of complex health challenges. Investors reacted positively to the news, with Supernus shares surging over 20% and Indivior shares climbing nearly 10% in premarket trading following the announcement.
